Company intelligence / Profile preview
EspeRare
Geneva, Switzerlandesperare.org ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
EspeRare has demonstrated proof of concept in humans for its lead programs. Its most advanced asset, efsudenermin alfa (targeting EDA), has reached Phase 2 clinical trials for X-linked hypohidrotic ectodermal dysplasia. Rimeporide, targeting NHE1 inhibition, was developed through a repositioning strategy and reached Phase 1 for Duchenne muscular dystrophy. The foundation specializes in repositioning or rescuing existing compounds with potential application to rare diseases and has received orphan drug designations from both US and EU regulators.
- Therapeutic areas
- Rare Diseases
- Modalities
- Small moleculeFusion proteinProteinEnzyme replacement therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Merck SeronoPharmaceutical companiesBiotechsAcademia/patient organizations
Beyond the preview
Go deeper on EspeRare.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EspeRare.